Prof. Dr. Richard Dodel

Aigner R, Hack J, Eschbach D, Ruchholtz S, Knobe M, Dodel R, Buecking B (2018) Is treatment of geriatric hip fracture patients cost-covering? Results of a prospective study conducted at a German University Hospital. Arch Orthop Trauma Surg. 138(3):331-337.

Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M (2018) Use of antidementia drugs in German patients with Alzheimer's disease. Int Clin Psychopharmacol. 33(2):103-110.

Heßmann P, Dreier M, Brandes I, Dodel R, Baum E, Müller MJ, Balzer-Geldsetzer M (2018) Differences Between Self- and Proxy-Assessment of Health-Related Quality of Life in Patients with Mild Cognitive Impairment and Alzheimer's Disease. Psychiatr Prax. 45(2):78-86.

Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M (2018) Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease. Pharmacopsychiatry (ahead of print)

Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M (2018) Antidepressant medication in a German cohort of patients with Alzheimer's disease. Int J Clin Pharmacol Ther. 56(3):101-112.

Reed C, Barrett A, Lebrec J, Dodel R, Jones RW, Vellas B, Wimo A, Argimon JM, Bruno G, Haro JM (2017) How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease? Health Qual Life Outcomes. 15(1):16.

Reed C, Happich M, Argimon JM, Haro JM, Wimo A, Bruno G, Dodel R, Jones RW, Vellas B, Belger M (2017) What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study. J Alzheimers Dis. 57(3):797-812.

Voigt-Radloff S, de Werd MM, Leonhart R, Boelen DH, Olde Rikkert MG, Fliessbach K, Klöppel S, Heimbach B, Fellgiebel A, Dodel R, Eschweiler GW, Hausner L, Kessels RP, Hüll M (2017) Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning. Alzheimers Res Ther. 9(1):22.

Lueken U, Evens R, Balzer-Geldsetzer M, Baudrexel S, Dodel R, Gräber-Sultan S, Hilker-Roggendorf R, Kalbe E, Kaut O, Mollenhauer B, Reetz K, Schäffer E, Schmidt N, Schulz JB, Spottke A, Witt K, Linse K, Storch A, Riedel O (2017) Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease. Int J Methods Psychiatr Res. 26(4). doi: 10.1002/mpr.1564.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group (2017) Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 32(6):853-864.

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 32(7):995-1005.

Jones RW, Lebrec J, Kahle-Wrobleski K, Dell'Agnello G, Bruno G, Vellas B, Argimon JM, Dodel R, Haro JM, Wimo A, Reed C (2017) Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes. Dement Geriatr Cogn Dis Extra 7(1):87-100.

de Roos P, Bloem BR, Kelley TA, Antonini A, Dodel R, Hagell P, Marras C, Martinez-Martin P, Mehta SH, Odin P, Chaudhuri KR, Weintraub D, Wilson B, Uitti RJ (2017) A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. J Parkinsons Dis. 7(3):533-543.

Enders D, Balzer-Geldsetzer M, Riedel O, Dodel R, Wittchen HU, Sensken SC, Wolff B, Reese JP (2017) Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples. Eur Neurol. 78(3-4):128-136.

Buecking B, Eschbach D, Knobe M, Oberkircher L, Balzer-Geldsetzer M, Dodel R, Sielski R, Doering B, Ruchholtz S, Bliemel C (2017) Predictors of noninstitutionalized survival 1 year after hip fracture: A prospective observational study to develop the Marburg Rehabilitation Tool for Hip fractures (MaRTHi). Medicine (Baltimore) 96(37):e7820.

Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, Verhey FRJ, Winblad B (2017) Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. J Alzheimers Dis. 60(4):1477-1487.

Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M (2017) Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany. Int J Psychiatry Clin Pract. 13:1-8.

Reed C, Belger M, Vellas B, Andrews JS, Argimon JM, Brono G, Dodel R, Jones RW, Wimo A, Haro JM (2016) Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease. Int. Psychogeriatr. 28(2):247-59.

Heßmann P, Seeberg G, Reese JP, Dams J, Baum E, Müller MJ, Dodel R, Balzer-Geldsetzer M (2016) Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings. J Alzheimers Dis. 51(2):545-61.

Fengler S, Roeske S, Heber I, Reetz K, Schulz JB, Riedel O, Wittchen HU, Storch A, Linse K, Baudrexel S, Hilker R, Mollenhauer B, Witt K, Schmidt N, Balzer-Geldsetzer M, Dams J, Dodel R, Gräber S, Pilotto A, Petrelli A, Fünkele S, Kassubek J, Kalbe E (2016) Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. Psychol Med. 46(11):2275-86.

Belger M, Haro JM, Reed C, Happich M, Kahle-Wrobleski K, Argimon JM, Bruno G, Dodel R, Jones RW, Vellas B, Wimo A (2016) How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study. BMC Med Res Methodol. 16:83.

Kalbe E, Rehberg SP, Heber I, Kronenbuerger M, Schulz JB, Storch A, Linse K, Schneider C, Gräber S, Liepelt-Scarfone I, Berg D, Dams J, Balzer-Geldsetzer M, Hilker R, Oberschmidt C, Witt K, Schmidt N, Mollenhauer B, Trenkwalder C, Spottke A, Roeske S, Wittchen HU, Riedel O, Dodel R (2016) Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry. 87(10):1099-105.

Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, Timmermann L, Schnitzler A, Reese JP, Dodel R; EARLYSTIM-investigators (2016) Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications. Mov Disord. 31(8):1183-91.

Kortland LM, Alfter A, Bähr O, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, Reese JP, Runge U, Senft C, Steinmetz H, Rosenow F, Strzelczyk A (2016) Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany. Epilepsia. 57(12):2056-2066.